8-K: 20/20 Biolabs Enters Standstill with Investor, Faces Nasdaq Bid Price Concern

20/20 Biolabs, Inc. has entered into a 120-day standstill agreement with Streeterville Capital, LLC, while also receiving a notice from Nasdaq regarding non-compliance with the minimum bid price rule.

Summary

• 20/20 Biolabs, Inc. (the Company) has entered into a Standstill Agreement with Streeterville Capital, LLC (Streeterville), effective July 16, 2026.
• This agreement restricts Streeterville from converting its Series E convertible preferred stock into common stock for 120 days, unless the common stock trades at least 10% above the Nasdaq Minimum Price on any given trading day.
• The Company also received a notification from The Nasdaq Stock Market LLC (Nasdaq) on July 17, 2026, stating it is not in compliance with the $1.00 minimum closing bid price requirement.
• The Company has been granted a 180-day compliance period, until January 13, 2027, to regain compliance.
• To comply, the common stock's closing bid price must be at least $1.00 for ten consecutive business days within this period.
• The Company is considering options to cure the deficiency and regain compliance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the Nasdaq delisting risk and the ongoing dilution concerns from convertible preferred stock, despite the temporary relief provided by the standstill agreement.

Positives

• The Standstill Agreement provides a temporary period of stability by restricting conversion of preferred stock, potentially preventing further dilution in the short term.
• The Company has a 180-day compliance period to regain the minimum bid price on Nasdaq, offering a window to implement corrective measures.
• The Company is actively considering options to address the bid price deficiency.

Negatives

• The Company is not in compliance with Nasdaq's minimum bid price rule ($1.00) for 30 consecutive business days.
• The potential for delisting from Nasdaq if compliance is not achieved within the given periods.
• The conversion price for Series E preferred stock is subject to a floor price of 20% of the Minimum Price as defined in Nasdaq Rule 5635, indicating a significant discount to market price if conversions occur.
• The Standstill Agreement can terminate immediately upon any breach or Event of Default, potentially allowing immediate conversion by Streeterville.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price rule could lead to delisting.
• The Company may need to consider significant strategic actions, potentially including a reverse stock split or other measures, to meet the bid price requirement.
• If the Standstill Agreement terminates due to a breach or Event of Default, Streeterville could convert its preferred stock, leading to substantial dilution.
• The terms of the Series E convertible preferred stock allow for conversion at a price significantly below current market prices if certain conditions are met, posing a risk of future dilution.

Future Outlook

The Company has a 180-day period to regain compliance with Nasdaq's minimum bid price rule. The Company intends to monitor its stock price and may consider options to cure the deficiency. The Standstill Agreement is in effect for 120 days, after which Streeterville may convert its preferred stock without the 10% premium, subject to the terms of the original agreement.

Management Comments

• The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to cure the deficiency and regain compliance with the Bid Price Rule within the compliance period(s) under Nasdaq's Listing Rules.

Industry Context

StockSavvy.ai notes that Nasdaq listing compliance issues, particularly concerning minimum bid prices, are common for smaller-cap companies facing market volatility or investor concerns. The standstill agreement suggests an ongoing negotiation or management of a significant investor's position, which is typical in such situations.

Stakeholder Impact

• Shareholders: Potential for significant dilution if preferred stock is converted, and risk of delisting from Nasdaq which could severely impact liquidity and valuation.
• Creditors: Increased risk if the company's ability to maintain its listing is jeopardized, potentially affecting its access to future financing.
• Management: Faces pressure to execute strategies that will restore the stock price to meet Nasdaq requirements.

Next Steps

• The Company must regain compliance with Nasdaq's minimum bid price rule by January 13, 2027.
• The Company may explore options to cure the bid price deficiency.
• The Standstill Agreement remains in effect for 120 days from July 16, 2026.
• Streeterville Capital may convert Series E preferred stock after the standstill period or if the conditions are met.

Key Dates

Recommendation

The company is facing significant headwinds with Nasdaq compliance and potential dilution. While the standstill agreement offers a temporary reprieve, the underlying issues remain. A 'hold' recommendation reflects the uncertainty and the need for the company to demonstrate a clear path to resolving its listing requirements and financial structure before a more positive outlook can be considered.

Keywords

Nasdaq compliance, Bid Price Rule, Convertible Preferred Stock, Standstill Agreement, Streeterville Capital, Delisting risk, Equity financing, Dilution